Iovance Biotherapeutics (IOVA) Accounts Payables (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Accounts Payables of $37.4 million for Q1 2026, up 31.45% year-over-year from $28.5 million in Q1 2025, and up 69.01% quarter-over-quarter from $22.2 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Accounts Payables (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Accounts Payables for 17 consecutive years, with $37.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 31.45% year-over-year to $37.4 million; the TTM figure through Mar 2026 stood at $37.4 million (up 31.45% YoY), while the FY2025 annual figure was $22.2 million, down 19.45% from the prior year.
- Accounts Payables climbed to $37.4 million in Q1 2026 per IOVA's latest filing, from $22.2 million in the prior quarter.
- Across five years, Accounts Payables topped out at $37.4 million in Q1 2026 and bottomed at $19.3 million in Q3 2023.
- Historically, Accounts Payables has averaged $27.4 million across 5 years, with a median of $27.5 million in 2024.
- Annual changes were most pronounced in 2022 — Accounts Payables soared 99.12% — and 2023, when it dropped 20.54%.
- Iovance Biotherapeutics' Accounts Payables stood at $26.6 million in 2022, then increased by 24.51% to $33.1 million in 2023, then retreated by 16.95% to $27.5 million in 2024, then declined by 19.45% to $22.2 million in 2025, then jumped by 69.01% to $37.4 million in 2026.
- Business Quant data shows IOVA's Accounts Payables at $37.4 million in Q1 2026, $22.2 million in Q4 2025, and $31.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 26.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.21 Mn |
| Mar 31, 2026 | 37.45 Mn |
| Dec 31, 2025 | 22.16 Mn |
| Sep 30, 2025 | 31.24 Mn |
| Jun 30, 2025 | 32.00 Mn |
| Mar 31, 2025 | 28.49 Mn |
| Dec 31, 2024 | 27.51 Mn |
| Mar 31, 2024 | 25.70 Mn |
| Dec 31, 2023 | 33.12 Mn |
| Sep 30, 2023 | 19.27 Mn |
| Jun 30, 2023 | 31.16 Mn |
| Mar 31, 2023 | 31.57 Mn |
| Dec 31, 2022 | 26.60 Mn |
| Sep 30, 2022 | 24.26 Mn |
| Jun 30, 2022 | 20.01 Mn |
| Mar 31, 2022 | 20.45 Mn |
| Dec 31, 2021 | 27.38 Mn |
| Sep 30, 2021 | 12.18 Mn |
| Jun 30, 2021 | 21.91 Mn |
| Mar 31, 2021 | 13.37 Mn |